(NASDAQ: CING) Cingulate's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 116.73%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.58%.
Cingulate's revenue in 2026 is $0.On average, 7 Wall Street analysts forecast CING's revenue for 2026 to be $13,230,343, with the lowest CING revenue forecast at $0, and the highest CING revenue forecast at $55,340,403. On average, 5 Wall Street analysts forecast CING's revenue for 2027 to be $86,868,892, with the lowest CING revenue forecast at $53,637,622, and the highest CING revenue forecast at $143,317,455.
In 2028, CING is forecast to generate $153,399,003 in revenue, with the lowest revenue forecast at $139,148,343 and the highest revenue forecast at $166,730,702.